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Abstract. Cervical cancer is the second leading cause of
death among female patients with cancer in the world. Our
aim was to analyze cervical cancer cases, in the
Southwestern Transdanubian Region of Hungary, with regard
to human papillomavirus (HPV) genotype and histological
and clinical grading. After HPV testing and genotyping, the
expressions of eight different pre-microRNAs (miR-21, miR-
27a, miR-34a, miR-146a, miR-155, miR-196a, miR-203,
miR-221) in formalin-fixed paraffin-embedded (FFPE)
primary human cervical cancer samples were evaluated with
the help of the LightCycler 480 PCR System (Roche).
Statistically significant overexpression of miR-21 (p=0.004),
miR-27a (p=0.018), miR-34a (p<0.001), miR-155 (p=0.021),
miR-196a (p=0.032), miR-203 (p=0.037) and miR-221
(p=0.017) were observed in squamous cell carcinoma,
regardless of HPV status and clinical grading. Significant
overexpression of miR-21 (p=0.004), miR-27a (p=0.02),
miR-34a (p<0.001), miR-196a (p=0.027) and miR-221
(p=0.031) was characteristic of HPV-positive squamous cell
carcinomas in contrast to adenocarcinomas of the same HPV
status. 
Even though widespread screening programs and the
introduction of HPV vaccines have reduced its morbidity and
mortality rates in the past decade, cervical cancer is still the
second leading cause of death among women worldwide,
with an estimated 530,000 deaths per year (age-standardized
global incidence rates: 15.3 and mortality rates: 7.8 in 2008)
(1). The worldwide prevalence of cervical adenocarcinoma
has increased from 5% in 1950-60 to 20-25% in several
regions of the world, including Europe and the US (2, 3).
According to the latest data from 2011, cervical
adenocarcinoma accounts for more than 25% of all newly-
diagnosed cases of cervical cancer, particularly affecting
young women, and at the same time it remains a problem
even in screened populations (4). It needs to be emphasized
that many women diagnosed with cervical adenocarcinoma
(ACC) are young (5). Since human papillomavirus (HPV)
negativity is more frequently proven in this tumor subtype
than in squamous cell carcinoma (SCC), incidence rates
might reach even higher magnitudes in the upcoming
decades of the post-vaccination era. On the other hand, skip
lesions often seen in ACC make early identification of pre-
cancerous and cancerous lesions more difficult.
The role of oncogenic or high-risk HPV viruses in cervical
carcinogenesis is indisputible, yet not fully understood.
Oncogenic HPV positivity is registered in more than 99% of
cervical cancer cases. HPV positivity and especially
persistant HPV infection, is predictive in the risk assessment
of pre-malignant lesions (6). The prevalence of HPV
infection is the highest in younger women (under 30 years
old) and current attempts focus on reducing the number of
transient infections identified. HPV 16 is the most common
genotype in women without cytological alterations
worldwide, although it is also the most common type of
HPV infection in ACC and SCC (7). The current situation in
Hungary is best described by Galamb et al. in their analysis
of data from 2007-2011 on the first HPV center in Hungary.
It is worth mentioning that HPV type was unidentifiable in
more than 25% of the patients overall, and in more than 10%
of the patients with cytological abnormalities (8).
What we also need to consider is that HPV infection alone
is insufficient to induce malignant transformation, other, as
yet unidentified genetic alterations (individual susceptibility)
are also involved in the process. The focus has already turned
to regulatory networks in the field of cancer research, with an
emphasis on microRNAs, since they play key roles in vital
biological functions, including development, differentiation,
2561
Correspondence to: Katalin Gocze, Institute of Public Health,
University of Pecs, Szigeti ut 12., Pecs H-7624, Hungary. E-mail:
katag@hotmail.com
Key Words: Cervical cancer, microRNA expression, HPV, clinical
grading.
ANTICANCER RESEARCH 33: 2561-2568 (2013)
Unique MicroRNA Expression Profiles in Cervical Cancer
KATALIN GOCZE1, KATALIN GOMBOS1, KRISZTINA JUHASZ1, KRISZTINA KOVACS2, BELA KAJTAR2, 
MARTA BENCZIK3, PETER GOCZE4, BALAZS PATCZAI1, ISTVAN ARANY5 and ISTVAN EMBER1
Institutes of 1Public Health and 2Pathology, University of Pecs, Pecs, Hungary;
3Genoid Laboratory, Budapest, Hungary;
4Department of Obstetrics and Gynecology, University of Pecs, Pecs, Hungary;
5Department of Pediatrics, Division of Pediatric Nephrology, 
University of Mississippi Medical Center, Jackson, MS, U.S.A.
0250-7005/2013 $2.00+.40
metabolism and apoptosis (9, 10). In the process of
understanding carcinogenesis, the analysis of miRNA
expression has become one of the focal points in molecular
biology. Genome-wide profiling of miRNA signatures has
indicated that altered miRNA expression is common in most
human tumors. These small, non-coding RNA sequences that
regulate gene expression at the post-transcriptional level in a
diversified network, might function as oncogenes or tumor
suppressors by modulating oncogenic or tumor suppressive
pathways (9, 10). De-regulation of miRNA expression and
their contribution to cancer development and progression have
already been proven in many malignancies (11, 12).
In high-risk HPV infections, the regulation of cellular
oncogenic and tumor-suppressive miRNAs is altered, leading
to differences in expression profiles. This is most probably
generated by viral proteins, mainly E6 and E7 (13-15).
Changes in the expressions of miR-34a, miR-21, miR-203
and miR-218 are all attributed to interactions of these two
viral oncoproteins, although not every detail of the network
of events has been fully discovered yet (16-22). MiRNA
genes are often observed at HPV integration sites, associated
with cancer of various types (23). On the other hand, cellular
miRNAs, such as miR-125b and miR-203, may also play an
important role in the regulation of viral gene expression and
DNA replication (24, 25). The detailed description of the
involvement of specific miRNAs might help in the
identification of interactions of viral and cellular miRNAs
and in understanding the pathogenesis of cervical cancer.
The fact that miRNA profiling overcomes the limitation of
age and consequent degradation in formalin-fixed paraffin-
embedded (FFPE) samples, unlike mRNAs, makes the
approach even more appealing.
The role of miRNAs has already been investigated to an
extent and results are diverse, showing high variability,
especially in normal cervical tissues. Data regarding the
magnitude of deregulation is sometimes also heterogeneous.
In 2007, Lui et al. showed significantly reduced expression
of miR-143 and increased expression of miR-21 in human
cervical cancer samples of different histotypes matched to
normal cervical samples using direct sequencing (21). In
cervical tissue samples Lee et al. highlighted the up-
regulation of miR-21, miR-29a, mir-146a, miR-155 and the
down-regulation of miR-203, among others, using TaqMan
quantitative real-time polymerase chain reaction (PCR) (19).
When studying expressions in cervical tissues and in cervical
cell lines, Wang et al. found that miR-29a, miR-143, miR-
145, miR-146a, miR-199a, miR-218 were down-regulated
and miR-21, miR-155 were up-regulated (18). Pereira et al.
indicated lower expressions of miR-29a, miR-143, miR-145,
miR-199a and miR-203, with the simultaneous up-regulation
of miR-196a with transition from normal cervix to atypical
dysplasia to cancer. They observed high expression
variability between their samples of SCC, high-grade
cervical squamous intraepithelial lesion (H-SIL), low-grade
cervical squamous intraepithelial lesion (L-SIL) and normal
cervical epithelial tissues, but they were able to identify de-
regulated miRNAs (26). 
Materials and Methods
The study was approved by the Ethics Committee of Pécs University
(3440.316-8331/KK41/2009). FFPE human primary cervical
carcinoma tissue samples (ACC: n=22 and SCC: n=25) from
archives of the Pathology Department of Pécs University were
randomly selected for further analysis. Samples were obtained from
patients diagnosed and treated between 2007-2010 at the Department
of Obstetrics and Gynaecology, Pécs University. Following HPV
genotyping, performed by Genoid Laboratory, our aim was to
compare the expression of eight different pre-microRNAs (miR-21,
miR-27a, miR-34a, miR-146a, miR-155, miR-196a, miR-203, miR-
221) in the two most common histological subtypes of cervical
cancer. The panel of miRNAs was systematically chosen, based on
published data and previous experience regarding expression profiles
in epithelial tumors. To investigate miRNA expression profiles in
cervical cancer, the first step taken was deparaffination of sample
materials (three sections 8-10 μm each) using xylol and absolute
alcohol in 1.5 ml volume. After deparaffination, we isolated total
miRNA using High Pure microRNA Isolation Kit (Roche,
Mannheim, Germany) according to the manufacturer’s instructions,
followed by reverse transcription of 5 μl of extracted miRNA with
random hexamer primers using Transcriptor First Strand cDNA
Synthesis Kit (Roche), resulting in a total volume of 50 μl in a
LightCycler® 2.0 (Roche). RNA purity was measured using the
A260/A280 ratio and was found to be between 1.9 and 2.1. The
expression of miRNA precursors was determined using quantitative
real-time PCR using a standard LightCycler® 480 SYBR Green I
Master PCR kit protocol in the LightCycler® 480 Instrument
(Roche). The 20 μl PCR mix included 5 μl template cDNA, 10 μl
PCR Master Mix, 2 μl pre-miRNA-specific primer [10 μM solution
of each pair of primers (Exiqon), diluted and stored at 4˚C in PCR
tubes] and 3 μl PCR grade water. The reactions were incubated in a
96-well plate at 95˚C for 10 min, followed by 55 cycles of
denaturation at 95˚C for 10 s, annealing at 55˚C for 20 s and
extension at 72˚C for 15 s. Runs were concluded with quantification
and one cycle melting curve analysis at 95˚C for 5 s, at 65˚C for 1
min, with continuous acquisition 97˚C. All assays, including no
template controls, were carried out in triplicate. Inter-run calibrators
were used to calculate correction factors to remove the run-to-run
differences. Data normalization was performed using 5S rRNA and
U6 snRNA as endogenous references. A normalization factor was
calculated based on the arithmetic mean quantification cycle (Cq)
value of reference genes. Relative quantification of miRNA
expression was calculated by the 2–ΔΔCT method. Normalized
relative quantities were used for further statistical analysis regarding
the effects of several variables, carried out in IBM SPSS Statistics
Version 20 with level of significance set at p<0.05. 
Results
The median age was lower for patients with AC than for those
with SCC and the rate of high-risk HPV in SCC and AC was
76% and 68.18%, respectively, which was lower than
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previously expected, based on published data (7). Out of the
high-risk HPV types, 16 and 18 were the most frequently
registered, with an overall prevalence of 78.95% in SCC and
86.67% in AC. Type 16 was more abundant (14:1) in SCC,
than in AC, where the ratio of 16 and 18 was almost equal
(7:6). The difference was statistically significant between the
two histopathological subtypes (p=0.041 using Pearson χ² test). 
miRNA expression profile in correlation with histopathology.
The miRNA profiling data were analyzed to identify miRNAs
that significantly correlated with histopathological findings.
The overall expression profiles based on the eight chosen
microRNAs were distinctive of the histological characteristics
in cervical cancer samples. The comparison of targeted
miRNA expression profiles of AC and SCC reveals distinctive
characteristics (Figure 1). The expression levels of all
miRNAs were higher in SCC than in AC. The difference
reached the level of statistical significance in almost all cases
using independent sample t-tests: miR-21, p=0.004; miR-27a,
p=0.018; miR-34a, p<0.001; miR-155, p=0.021; miR-196a,
p=0.032; miR-203, p=0.037; and miR-221, p=0.017; the only
exception was miR-146a, where the difference lacked
significance (Figure 2).
Correlation of miRNA expression with HPV status. On
comparing the microRNA expression of HPV-negative and 
-positive cervical carcinomas, the expressions of miR-21,
miR-27a, miR-146a, miR-196a, miR-203, miR-221 were
higher and the levels of miR-34a and miR-155 were lower
in the HPV-positive group, although the difference was not
significant after statistical analysis (Figure 3). After we
summarized the targeted miRNA profiles of AC and SCC in
conjunction with HPV status, relevant alterations stood out.
On detailed statistical analysis, we found statistically
significant differences between HPV-positive AC and SCC
in the case of miR-21 (p=0.004), miR-27a (p=0.02), miR-
34a (p<0.001), miR-196a (p=0.027) and miR-221 (p=0.031)
(independent samples t-test). As for the statistical analysis of
HPV-negative AC and SCC, the differences did not reach the
level of statistical significance (Figure 4). As we assessed the
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Figure 1. Overview of expression profiles of the targeted miRNAs in adenocarcinoma (AC) and squamous cell carcinoma (SCC).
Figure 2. Expression (relative to U6 snRNA, after normalisation) in squamous cell carcinoma (SCC) and adenocarcinoma (AC) for the targeted
miRNAs.
histopathological diagnosis in parallel with the HPV status,
the patterns of the expressions of the selected miRNAs
showed greater variability. In the case of SCC with HPV
positivity, we found higher levels of miR-21, miR-146a,
miR-196a, miR-221 than in HPV-negative SCC. None of the
differences reached statistical significance, however. As for
miR-34a, miR-155 and miR-203, HPV-positive SCC cases
had lower levels of expression. The differences, again, were
not statistically significant. In AC, HPV positivity featured
higher miRNA expression than HPV negativity. The only
exception was miR-146a. The differences did not reach the
required level of statistical significance.
MiRNA expression according to clinical grading. The clinical
status was assessed using the International Federation of
Gynecology and Obstetrics (FIGO) grades. The studied
samples were from patients with various clinical stages of
cervical cancer (FIGO 0: 5, FIGO I: 23, FIGO II: 7, FIGO
III: 9, FIGO IV: 2). Statistical evaluation identified distinct
correlations between the following targeted miRNA
expression levels and the extent of cervical cancer regardless
of histopathology: miR-21, p<0.001; miR-27a, p=0.042;
miR-34a, p=0.016; miR-146a, p=0.014; and miR-221,
p=0.036 (one-way ANOVA) (Figure 5). We compared the
different stages in the next phase of the statistical analysis
(independent samples t-test). A statistically significant
difference was obtained in the case of miR-21 (p=0.001) and
miR-203 (p=0.002), comparing FIGO 0 with FIGO I, with
each miRNA having a higher level of expression in FIGO I
(Figure 6A). The same pattern was distinguishable for the
relationship of FIGO I and II, where the expressions were
consistently higher in FIGO II. Statistical significance was
detectable for miR-221 (p=0.015) (Figure 6B). Only the
expressions of miR-34a and miR-146a were higher in FIGO
III than in FIGO II and none of the deviations had statistical
significance (Figure 6C). In FIGO IV, most miRNA
expressions (miR-27a, miR-34a, miR-155, miR-196a, miR-
203 and miR-221) were higher than in FIGO III. Relatively
lower expressions of miR-21 and miR-146a characterized
FIGO IV from FIGO III. The degree of divergence reached
the level of significance in the case of miR-34a (p=0.037)
and miR-196a (p=0.007) (Figure 6D). Multivariate tests
(two- and three-way ANOVA, logistic regression) found no
significant interaction between the examined parameters.
Discussion
In this study, we have shown that it is possible to
differentiate the two most frequent histological types of
cervical cancer based on miRNA profiles and even though
the diagnosis of cervical cancer is currently based on clinical
and pathological examination, our findings raise the
possibility of using miRNA expression profiles in tumor type
distinction and maybe even in prediction in the case of pre-
neoplastic lesions. There are scarcely any published data
regarding the differences in microRNA profiles based on
histopathology. We also took the relevance of HPV infection
into consideration, since it is thought to be the most
important factor for transition from normal cervical
epithelium to pre-neoplastic cervical intraepithelial neoplasia
that subsequently transforms to invasive cervical cancer.
However, the pathogenic mechanism is still unknown.
Proteins encoded by E6 and E7 genes of high-risk HPVs
cause degradation and/or inactivation of p53 and Rb proteins
(13). HPV-associated miRNAs (miR-34a, miR-146a, miR-
203), directly or indirectly regulated by E5-E7 oncogenic
proteins (17, 24), play an important role in the initiation and
progression of cervical cancer.
Our analysis of expression profiles for the targeted
miRNAs indicated significant differences in the case of miR-
21, miR-27a, miR-34a, miR-155, mir-196a, miR-203 and
miR-221 between the two histotypes. We verified significant
differences between the HPV-positive two histotypes in the
case of miR-21, miR-27a, miR-34a, miR-196a and miR-221.
The miR-21 gene is located on chromosome 17q23.2, which
is inside the common fragile site FRA17B. This region has
been frequently found to be amplified in several solid tumors
(27), which seems to be consistent with the fact that miR-21
is elevated in these cancers. One of the HPV16 integration
loci is at 17q23.2 (28, 29), suggesting that the expression of
cellular miRNA genes at or near HPV integration sites may
contribute to the tumor phenotype. Here, we have shown that
the expression of miR-21 was up-regulated in patients with
HPV infection, implying that HPV infection induces
carcinogenesis probably through altering expression of some
oncomiRs such as miR-21. We found that miR-21 is
abundantly expressed in HPV-positive samples overall and
separately in both histotypes. The overexpression of miR-21
was also consistently increasing with clinical grade (FIGO 0-
III). Yao and Lin indicated that miR-21 has multiple functions
ANTICANCER RESEARCH 33: 2561-2568 (2013)
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Figure 3. Overview of expression profiles of the targeted miRNAs
(relative to U6 snRNA, after normalisation) in human papillomavirus
(HPV)-positive and -negative cervical cancer.
in the development of cervical squamous cancer by showing
that miR-21 could dramatically increase cell proliferation,
inhibit apoptosis and promote cell migration in HPV16-
positive cervical squamous cancer lines. In the same study
they also proved that overexpression of miR-21 was
associated with advanced disease and lymph node metastasis
(30). Scmitz et al. studied HPV integration sites and they
concluded that integration is not an entirely random event but
also involves preferred chromosomal sites, including near
miRNAs. Out of the 75 miRNAs in the neighbourhood of
integration sites many have already been associated with
cancer and of these miR-34a, miR-21 and miR-27a are
expressed in cervical cancer cells (31). Previous studies
indicated that the HPV E7 protein down-regulates miR-203
expression upon differentiation, which may occur through the
mitogen-activated protein (MAP) kinase/protein kinase C
(PKC) pathway (32). One target of miR-203 is the p63 family
of transcription factors, and HPV-positive cells maintain
significantly higher levels of these factors upon differentiation
than do normal keratinocytes. Melar-New and Laimins
concluded that high levels of miR-203 are inhibitory to HPV
amplification and that HPV proteins act to suppress
expression of this microRNA to allow productive replication
in differentiating cells. In addition McCluggage has already
declared that p63 is a useful marker of squamous neoplasms
within the cervix (33), which might as well imply the
importance of miR-203. MiR-146a is also considered to be
cervical cancer specific, but it was proved to be independent
from histotype or HPV-infection. Latter has already been
indicated by Wang et al. (18). 
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Figure 4. Targeted miRNA expressions (relative to U6 snRNA, after normalisation) in HPV-positive adenocarcinoma (AC) and squamous cell
carcinoma (SCC).
Figure 5. Targeted miRNA expressions (relative to U6 snRNA, after normalisation) in correlation with FIGO grade.
Conclusion
Even though the small sample size was a known limitation,
the p53-induced miR-34a together with miR-21, miR-27a,
miR-155, miR-203 and miR-221 can be useful predictive and
prognostic biomarkers and will induce more detailed
investigations for future verification. Since miRNA expression
is highly preservative, sequential and tissue specific, the
observed alterations in miRNA expressions may be candidate
gene targets and might even serve as possible predictive
biomarkers in the field of prevention and therapeutic decision
support in response to the urgent need for earlier diagnosis,
more precise prognosis and successful, personalized therapy.
Further reduction in morbidity and mortality in the case of
cervical cancer can only be achieved with future
improvements in all levels of prevention. In the era of HPV
vaccines, for the generations to come, less frequent screening
is only acceptable if vaccination uptake is evenly distributed
across all social, economic and ethnic levels of populations.
Individual risk estimation is a pivotal point in primary
prevention, where higher efficacy is crucial. Cervical cancer,
like many other human cancer types, displays significantly
aberrant expression of a considerable number of cellular
miRNAs, both oncogenic and tumor-suppressive. Despite the
uncertainty regarding the functional effects of miRNA
dysregulation in the pathogenesis of cervical cancer,
determining miRNA expressions might help to assess factors
and risks playing a part in individual susceptibility and might
even help in the clinical projection regarding various
characteristics, including histopathological classification. 
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